Global AI in Pharmaceutical Market, 2025-2035

Description

List of Tables

Global AI in Pharmaceutical Market Size, Share & Trends Analysis by Technology (Machine Learning (ML), Deep Learning, Natural Language Processing (NLP), Computer Vision (in some reports), and Generative AI / Other Advanced AI Tech), By Application (Drug Discovery & Design, Clinical Trial Optimization / Clinical Decision Support, Research & Development, Precision Medicine / Personalized Treatment, Medical Imaging & Diagnostics, Regulatory Compliance & Safety / Pharmacovigilance), By Offering (Software Platforms, Services, and Hardware), By Deployment Mode (Cloud-Based, and On-Premises) and By End-User (Pharmaceutical & Biotechnology Companies, Hospitals & Healthcare Providers, Academic & Research Institutions, Contract Research Organizations (CROs), and Others), Forecast Period (2026-2035)

Industry Overview

AI in pharmaceutical market was valued at $2.0 billion in 2025 and is projected to reach $22.5 billion by 2035, growing at a CAGR of 27.5% during the forecast Period (2026-2035). The market is experiencing steady growth, driven by the increasing integration of advanced technologies across drug discovery, development, and clinical processes. AI tools such as machine learning and data analytics are being used to enhance efficiency, reduce timelines, and improve decision-making. The market is supported by rising investments, expanding healthcare data availability, and growing collaborations between pharmaceutical and technology companies. Additionally, the adoption of AI in precision medicine and clinical trials is contributing to broader market expansion.

Market Dynamics

Rising Drug Development Costs and Need for Efficiency

The increasing cost and complexity of drug development are major drivers for the adoption of AI in the pharmaceutical industry. Developing a single drug can take 10-17 years and cost up to billions of dollars, creating strong pressure on companies to improve productivity and reduce failure rates. AI technologies enable faster target identification, molecule screening, and predictive modeling, significantly lowering R&D costs and timelines. Studies indicate AI can reduce drug discovery timelines by around 25% and lower clinical trial costs by up to 70%, making it a critical tool for improving overall operational efficiency.

Growing Availability of Large-Scale Biomedical Data

The rapid expansion of healthcare data, including genomics, proteomics, clinical records, and real-world evidence, is accelerating the adoption of AI in pharmaceuticals. AI algorithms thrive on large datasets, enabling more accurate prediction of drug-target interactions and patient responses. The integration of multi-omics data and advanced analytics allows pharmaceutical companies to identify novel therapeutic pathways and optimize drug design with higher precision. This data-driven environment is a foundational factor supporting AI deployment across drug discovery and development processes.

Increasing Investment, Strategic Collaborations, and Industry Adoption

The pharmaceutical industry is witnessing strong investment momentum and partnerships focused on AI-driven innovation. A significant proportion of pharma executives are increasing AI investments, and billions of dollars are being directed toward AI collaborations and startups. Strategic alliances between pharmaceutical companies, biotech firms, and AI technology providers are accelerating the commercialization of AI-based drug discovery platforms. Recent multi-billion-dollar partnerships highlight how AI is becoming central to innovation strategies, enabling faster pipeline development and improved success rates in clinical trials.

Market Segmentation

Based on the technology, the market is segmented into machine learning (ML), deep learning, natural language processing (NLP), computer vision, and generative AI / other advanced AI tech.
Based on the application, the market is segmented into drug discovery & design, clinical trial optimization / clinical decision support, research & development, precision medicine / personalized treatment, medical imaging & diagnostics, regulatory compliance & safety / pharmacovigilance.
Based on the offering, the market is segmented into software platforms, services, and hardware, by deployment mode (cloud-based, and on-premises).
Based on the end-user, the market is segmented into pharmaceutical & biotechnology companies, hospitals & healthcare providers, academic & research institutions, contract research organizations (CROs), and others.

Drug Discovery & Design Segment to Grow at a Considerable Market Share

Drug discovery & design is expected to hold the largest share in the Global AI in Pharmaceutical Market. This dominance is primarily driven by the urgent need to reduce the time, cost, and high failure rates associated with traditional drug development processes. AI technologies, particularly machine learning and deep learning, are extensively utilized in early-stage drug discovery to identify novel drug targets, predict molecular behavior, and optimize compound selection with greater accuracy and speed.

Pharmaceutical and biotechnology companies are heavily investing in AI-powered drug discovery platforms to accelerate pipeline development and gain a competitive advantage. AI enables rapid screening of vast chemical libraries and improves hit-to-lead and lead optimization processes, which significantly enhances R&D productivity. Additionally, the growing integration of generative AI is further transforming drug design by enabling the creation of new molecular entities with desired properties.

Strategic collaborations between AI technology providers and pharmaceutical companies are also concentrated heavily in this segment, reinforcing its leadership position. As the demand for innovative therapies rises and patent cliffs pressure pharma revenues, companies are increasingly relying on AI-driven drug discovery solutions, making this segment the largest and most influential in the overall market.

Machine Learning (ML): A Key Segment in Market Growth

The machine learning (ML) segment represents the key driver of growth within the Global AI in Pharmaceutical Market, owing to its extensive application across the drug development lifecycle. ML algorithms are widely used for target identification, lead optimization, predictive modeling, and clinical trial design, enabling pharmaceutical companies to make faster and more accurate decisions. By analyzing vast and complex datasets such as genomic data, chemical libraries, and patient records, ML significantly improves the probability of success in drug discovery while reducing time and cost. Its ability to identify patterns, predict drug-target interactions, and optimize clinical outcomes has made it the most commercially viable and widely adopted AI technology in the sector. Moreover, continuous advancements in supervised and unsupervised learning techniques, along with integration with real-world data and electronic health records, are further strengthening their adoption. Pharmaceutical and biotechnology companies are increasingly investing in ML-based platforms to enhance pipeline productivity and reduce attrition rates. As a result, the ML segment continues to dominate market revenue and is expected to witness sustained growth, driven by its scalability, adaptability, and proven impact on accelerating pharmaceutical innovation.

Regional Outlook

The global AI in pharmaceutical market is further divided by geography, including North America (the US and Canada), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), and the Rest of the World (the Middle East & Africa, and Latin America).

North America Region to Hold a Substantial Growth Rate

In North America, the US dominates the global AI in Pharmaceutical market, holding a major share due to its advanced healthcare infrastructure, strong presence of leading pharmaceutical and biotechnology companies, and high adoption of innovative diagnostic and therapeutic technologies. The country benefits from significant investment in oncology research and development, supported by both government funding and private sector initiatives. Early adoption of advanced screening methods such as low-dose CT scans, along with widespread availability of molecular diagnostics and biomarker testing, has strengthened early detection rates and personalized treatment approaches.

Additionally, the US has a robust pipeline of targeted therapies and immunotherapies, with frequent regulatory approvals accelerating market growth. The presence of well-established healthcare facilities and specialized cancer centers further enhances access to cutting-edge treatments. Favorable reimbursement policies and high healthcare expenditure also contribute to the widespread use of premium diagnostic tools and therapies. Moreover, increasing awareness regarding early diagnosis and ongoing clinical trials continues to support innovation and adoption. These factors collectively position the United States as the leading country in the global lung cancer diagnostics and treatment landscape, driving continuous advancements and setting benchmarks for other regions.

Market Players Outlook

The major companies operating in the global AI in pharmaceutical market include Atomwise, Inc., Exscientia PLC, Insilico Medicine, Isomorphic Labs, and Recursion Pharmaceuticals, among others. Market players are leveraging partnerships, collaborations, mergers, and acquisitions to expand their businesses and develop innovative products to maintain their market positioning.

Recent Development

In April 2026, BD launched the BD Pyxis Pro Dispensing Solution and the BD Incada Connected Care Platform in Europe. This advanced medication dispensing system leverages automation and AI to enhance medication management, minimize disruptions, and improve operational efficiency, allowing clinicians to focus more on patient care. The Pyxis Pro offers flexible storage configurations, enhancing medication availability while incorporating robust security features for controlled substances. Additionally, the AI-driven BD Incada Analytics platform will be introduced to European healthcare facilities next year.
In September 2025, Mankind Pharma partnered with OpenAI to implement AI across its value chain, becoming one of the first Indian pharmaceutical companies to do so. This collaboration aims to enhance innovation and operational efficiency, benefiting customers, doctors, and the healthcare ecosystem. Mankind Pharma will utilize OpenAI Enterprise in various functions, such as field force enablement, digital marketing, R&D, manufacturing, and medical affairs. The integration of ChatGPT Enterprise is designed to convert extensive data into actionable insights and streamline operations, leveraging OpenAI's AI models, including GPT-5, to drive efficiencies from discovery to delivery.

The Report Covers:

Market value data analysis for 2025 and forecast to 2035.
Annualized market revenues ($ million) for each market segment.
Country-wise analysis of major geographical regions.
Key companies operating in the global AI in pharmaceutical market. Based on the availability of data, information related to new products and relevant news is also available in the report.
Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
Analysis of market-entry and market expansion strategies.
Competitive strategies by identifying 'who-stands-where' in the market.

Product Code: OMR2029364

1. Report Summary

Current Industry Analysis and Growth Potential Outlook
Global AI in Pharmaceutical Market Sales Analysis - Technology | Application | Offering | Deployment | Mode End-User ($ Million)
AI in Pharmaceutical Market Sales Performance of Top Countries
1.1. Research Methodology
Primary Research Approach
Secondary Research Approach
1.2. Market Snapshot

2. Market Overview and Insights

2.1. Scope of the Study
2.2. Analyst Insight & Current Market Trends
- 2.2.1. Key AI in Pharmaceutical Market Trends
- 2.2.2. Market Recommendations
2.3. Porter's Five Forces Analysis for the AI in Pharmaceutical Market
- 2.3.1. Competitive Rivalry
- 2.3.2. Threat of New Entrants
- 2.3.3. Bargaining Power of Suppliers
- 2.3.4. Bargaining Power of Buyers
- 2.3.5. Threat of Substitutes

3. Market Determinants

3.1. Market Drivers
- 3.1.1. Drivers For Global AI in Pharmaceutical Market: Impact Analysis
3.2. Market Pain Points and Challenges
- 3.2.1. Restraints For Global AI in Pharmaceutical Market: Impact Analysis
3.3. Market Opportunities
- 3.3.1. Opportunities For Global AI in Pharmaceutical Market: Impact Analysis

4. Competitive Landscape

4.1. Competitive Dashboard - AI in Pharmaceutical Market Revenue and Share by Manufacturers
AI in Pharmaceutical Application Comparison Analysis
Top Market Player Ranking Matrix
4.2. Key Company Analysis
- 4.2.1. Atomwise, Inc.
  - 4.2.1.1. Overview
  - 4.2.1.2. Application Portfolio
  - 4.2.1.3. Financial Analysis
  - 4.2.1.4. SWOT Analysis
  - 4.2.1.5. Business Strategy
- 4.2.2. Exscientia PLC
  - 4.2.2.1. Overview
  - 4.2.2.2. Application Portfolio
  - 4.2.2.3. Financial Analysis
  - 4.2.2.4. SWOT Analysis
  - 4.2.2.5. Business Strategy
- 4.2.3. Insilico Medicine
  - 4.2.3.1. Overview
  - 4.2.3.2. Application Portfolio
  - 4.2.3.3. Financial Analysis
  - 4.2.3.4. SWOT Analysis
  - 4.2.3.5. Business Strategy
- 4.2.4. Isomorphic Labs
  - 4.2.4.1. Overview
  - 4.2.4.2. Application Portfolio
  - 4.2.4.3. Financial Analysis
  - 4.2.4.4. SWOT Analysis
  - 4.2.4.5. Business Strategy
- 4.2.5. Recursion Pharmaceuticals
  - 4.2.5.1. Overview
  - 4.2.5.2. Application Portfolio
  - 4.2.5.3. Financial Analysis
  - 4.2.5.4. SWOT Analysis
  - 4.2.5.5. Business Strategy
4.3. Top Winning Strategies by Market Players
- 4.3.1. Merger and Acquisition
- 4.3.2. Application Launch
- 4.3.3. Partnership And Collaboration

5. Global AI in Pharmaceutical Market Sales Analysis by Technology ($ Million)

5.1. Machine Learning (ML)
5.2. Deep Learning
5.3. Natural Language Processing (NLP)
5.4. Computer Vision
5.5. Generative AI / Other Advanced AI Tech

6. Global AI in Pharmaceutical Market Sales Analysis by Application ($ Million)

6.1. Drug Discovery & Design
6.2. Clinical Trial Optimization / Clinical Decision Support
6.3. Research & Development
6.4. Precision Medicine / Personalized Treatment
6.5. Medical Imaging & Diagnostics
6.6. Regulatory Compliance & Safety / Pharmacovigilance

7. Global AI in Pharmaceutical Market Sales Analysis by Offering ($ Million)

7.1. Software Platforms
7.2. Services
7.3. Hardware

8. Global AI in Pharmaceutical Market Sales Analysis by Deployment Mode ($ Million)

8.1. Cloud-Based
8.2. On-Premises

9. Global AI in Pharmaceutical Market Sales Analysis by End-User ($ Million)

9.1. Pharmaceutical & Biotechnology Companies
9.2. Hospitals & Healthcare Providers
9.3. Academic & Research Institutions
9.4. Contract Research Organizations (CROs)
9.5. Others

10. Regional Analysis

10.1. North American AI in Pharmaceutical Market Sales Analysis - Technology | Application | Offering | Deployment Mode | End-User | Country ($ Million)
Macroeconomic Factors for North America
- 10.1.1. United States
- 10.1.2. Canada
10.2. European AI in Pharmaceutical Market Sales Analysis - Technology | Application | Offering | Deployment Mode | End-User | Country ($ Million)
Macroeconomic Factors for Europe
- 10.2.1. UK
- 10.2.2. Germany
- 10.2.3. Italy
- 10.2.4. Spain
- 10.2.5. France
- 10.2.6. Russia
- 10.2.7. Rest of Europe
10.3. Asia-Pacific AI in Pharmaceutical Market Sales Analysis - Technology | Application | Offering | Deployment Mode | End-User | Country ($ Million)
Macroeconomic Factors for Asia-Pacific
- 10.3.1. China
- 10.3.2. Japan
- 10.3.3. South Korea
- 10.3.4. India
- 10.3.5. Australia & New Zealand
- 10.3.6. ASEAN Countries (Thailand, Indonesia, Vietnam, Singapore, And Other)
- 10.3.7. Rest of Asia-Pacific
10.4. Rest of the World AI in Pharmaceutical Market Sales Analysis - Technology | Application | Offering | Deployment Mode | End-User | Country ($ Million)
Macroeconomic Factors for the Rest of the World
- 10.4.1. Latin America
- 10.4.2. Middle East and Africa

11. Company Profiles

11.1. Alphabet/Google Health
- 11.1.1. Quick Facts
- 11.1.2. Company Overview
- 11.1.3. Product Portfolio
- 11.1.4. Business Strategies
11.2. Atomwise
- 11.2.1. Quick Facts
- 11.2.2. Company Overview
- 11.2.3. Product Portfolio
- 11.2.4. Business Strategies
11.3. BenevolentAI
- 11.3.1. Quick Facts
- 11.3.2. Company Overview
- 11.3.3. Product Portfolio
- 11.3.4. Business Strategies
11.4. Evotec SE
- 11.4.1. Quick Facts
- 11.4.2. Company Overview
- 11.4.3. Product Portfolio
- 11.4.4. Business Strategies
11.5. Exscientia
- 11.5.1. Quick Facts
- 11.5.2. Company Overview
- 11.5.3. Product Portfolio
- 11.5.4. Business Strategies
11.6. Generate
- 11.6.1. Quick Facts
- 11.6.2. Company Overview
- 11.6.3. Product Portfolio
- 11.6.4. Business Strategies
11.7. IBM Corp.
- 11.7.1. Quick Facts
- 11.7.2. Company Overview
- 11.7.3. Product Portfolio
- 11.7.4. Business Strategies
11.8. Insilico Medicine
- 11.8.1. Quick Facts
- 11.8.2. Company Overview
- 11.8.3. Product Portfolio
- 11.8.4. Business Strategies
11.9. insitro
- 11.9.1. Quick Facts
- 11.9.2. Company Overview
- 11.9.3. Product Portfolio
- 11.9.4. Business Strategies
11.10. Isomorphic Labs
- 11.10.1. Quick Facts
- 11.10.2. Company Overview
- 11.10.3. Product Portfolio
- 11.10.4. Business Strategies
11.11. Microsoft
- 11.11.1. Quick Facts
- 11.11.2. Company Overview
- 11.11.3. Product Portfolio
- 11.11.4. Business Strategies
11.12. NVIDIA Corp.
- 11.12.1. Quick Facts
- 11.12.2. Company Overview
- 11.12.3. Product Portfolio
- 11.12.4. Business Strategies
11.13. Owkin
- 11.13.1. Quick Facts
- 11.13.2. Company Overview
- 11.13.3. Product Portfolio
- 11.13.4. Business Strategies
11.14. PathAI
- 11.14.1. Quick Facts
- 11.14.2. Company Overview
- 11.14.3. Product Portfolio
- 11.14.4. Business Strategies
11.15. Recursion Pharmaceuticals
- 11.15.1. Quick Facts
- 11.15.2. Company Overview
- 11.15.3. Product Portfolio
- 11.15.4. Business Strategies
11.16. Relay Therapeutics
- 11.16.1. Quick Facts
- 11.16.2. Company Overview
- 11.16.3. Product Portfolio
- 11.16.4. Business Strategies
11.17. Schrodinger
- 11.17.1. Quick Facts
- 11.17.2. Company Overview
- 11.17.3. Product Portfolio
- 11.17.4. Business Strategies
11.18. Standigm
- 11.18.1. Quick Facts
- 11.18.2. Company Overview
- 11.18.3. Product Portfolio
- 11.18.4. Business Strategies
11.19. Tempus
- 11.19.1. Quick Facts
- 11.19.2. Company Overview
- 11.19.3. Product Portfolio
- 11.19.4. Business Strategies
11.20. XtalPi
- 11.20.1. Quick Facts
- 11.20.2. Company Overview
- 11.20.3. Product Portfolio
- 11.20.4. Business Strategies